138 related articles for article (PubMed ID: 37323059)
1. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
D'Haens G; Peyrin-Biroulet L; Marks DJB; Lisi E; Liefaard L; Beaton A; Srinivasan N; Bouma G; Prasad N; Cameron R; Kayali Z; Tarzi R; Hanauer S; Sandborn WJ
Aliment Pharmacol Ther; 2023 Aug; 58(3):283-296. PubMed ID: 37323059
[TBL] [Abstract][Full Text] [Related]
2. Depletion of LAG-3
Ellis J; J B Marks D; Srinivasan N; Barrett C; Hopkins TG; Richards A; Fuhr R; Albayaty M; Coenen M; Liefaard L; Leavens K; Nevin KL; Tang S; Hughes SA; Fortunato L; Edwards K; Cui Y; Anselm R; Delves CJ; Charles E; Feeney M; Webb TM; Brett SJ; Schmidt TS; Stone J; Savage COS; Wisniacki N; Tarzi RM
Clin Pharmacol Ther; 2021 May; 109(5):1293-1303. PubMed ID: 33113155
[TBL] [Abstract][Full Text] [Related]
3. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
4. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
5. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
[TBL] [Abstract][Full Text] [Related]
6. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
7. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
9. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
Sandborn WJ; Bhandari BR; Randall C; Younes ZH; Romanczyk T; Xin Y; Wendt E; Chai H; McKevitt M; Zhao S; Sundy JS; Keshav S; Danese S
J Crohns Colitis; 2018 Aug; 12(9):1021-1029. PubMed ID: 29767728
[TBL] [Abstract][Full Text] [Related]
10. Randomized Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2831781 in Healthy Japanese and White Participants.
Liefaard L; Hajduk E; van den Berg F; Panoilia E; Bouma G; Lisi E; Srinivasan N; Cui Y; Gross AS; Tarzi R; Marks DJB
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1284-1293. PubMed ID: 36088650
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
12. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
[TBL] [Abstract][Full Text] [Related]
13. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
15. Etrolizumab for induction of remission in ulcerative colitis.
Rosenfeld G; Parker CE; MacDonald JK; Bressler B
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
[TBL] [Abstract][Full Text] [Related]
16. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
Danese S; Rudziński J; Brandt W; Dupas JL; Peyrin-Biroulet L; Bouhnik Y; Kleczkowski D; Uebel P; Lukas M; Knutsson M; Erlandsson F; Hansen MB; Keshav S
Gut; 2015 Feb; 64(2):243-9. PubMed ID: 25304132
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
18. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
19. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
[TBL] [Abstract][Full Text] [Related]
20. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
Mayer L; Sandborn WJ; Stepanov Y; Geboes K; Hardi R; Yellin M; Tao X; Xu LA; Salter-Cid L; Gujrathi S; Aranda R; Luo AY
Gut; 2014 Mar; 63(3):442-50. PubMed ID: 23461895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
